Publications by authors named "Marisa Capurro"
Article Synopsis
- Follicular lymphoma (FL) is the most common slow-growing non-Hodgkin lymphoma in the U.S. and Europe, but there's limited data from Latin America, particularly Chile.
- The study involved 722 Chilean patients diagnosed with FL from 2000 to 2019, revealing a median diagnosis age of 62, with many patients presenting advanced disease and a significant number affected by bone marrow involvement.
- Key findings show that adding rituximab to chemotherapy improves overall survival and response rate, while experiencing POD24 (progression of disease within 24 months) indicates much poorer survival outcomes.
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. The purpose of this study was to evaluate the clinical features, prognostic factors, and results of DLBCL that was treated in the cancer centers of the public health system in Chile and compare cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Patients And Methods: Patients age > 15 years who were treated in 18 cancer centers in the country between 2001 and 2017 were included.